22:52 , Jan 15, 2019 |  BC Week In Review  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
23:49 , Jan 14, 2019 |  BC Extra  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
18:36 , Nov 9, 2018 |  BC Week In Review  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
23:40 , Nov 8, 2018 |  BC Extra  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
16:42 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

AZ says Phase IIIb data of Bevespi Aerosphere in COPD are 'inconsistent with previous data'

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Bevespi Aerosphere glycopyrrolate/formoterol fumarate met one of three primary endpoints in the Phase IIIb AERISTO trial to treat moderate to very severe chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere was...
20:27 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

After Phase III results, AZ's COPD combo heading for submissions

AstraZeneca plc (LSE:AZN; NYSE:AZN) said triple combination therapy PT010 met six of seven primary endpoints evaluating lung function in the Phase III KRONOS trial to treat moderate to very severe chronic obstructive pulmonary disease (COPD)....
21:36 , Jan 26, 2018 |  BC Extra  |  Clinical News

After Phase III results, AZ's COPD combo heading for submissions

AstraZeneca plc (LSE:AZN; NYSE:AZN) said triple combination therapy PT010 met six of seven primary endpoints evaluating lung function in the Phase III KRONOS trial to treat moderate to very severe chronic obstructive pulmonary disease. The...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
20:52 , Mar 23, 2017 |  BC Week In Review  |  Company News

AZ, Circassia deal

AstraZeneca agreed to share rights to two chronic obstructive pulmonary disease therapies with Circassia. Circassia will lead promotion of AZ's Tudorza Pressair aclidinium bromide in the U.S., and may opt to acquire full U.S. rights....